Evidence map›Paper›PMID 38256375›Full record

ReviewMedicina (Kaunas, Lithuania)2024

Mild Behavioral Impairment in Parkinson's Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects.

Efthalia Angelopoulou, Anastasia Bougea, Alexandros Hatzimanolis, Leonidas Stefanis, Nikolaos Scarmeas, Sokratis Papageorgiou

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Behavioral disorders in Parkinson disease: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Efthalia AngelopoulouDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0002-1426-3384
Anastasia BougeaDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0003-3006-8711
Alexandros HatzimanolisDepartment of Psychiatry, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Leonidas StefanisDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Nikolaos ScarmeasDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-6453-8908
Sokratis PapageorgiouDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-8863-3635
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropsychiatric symptoms (NPS), including depression, anxiety, apathy, visual hallucinations, and impulse control disorders, are very common during the course of Parkinson's disease (PD), occurring even at the prodromal and premotor stages. Mild behavioral impairment (MBI) represents a recently described neurobehavioral syndrome, characterized by the emergence of persistent and impactful NPS in later life, reflecting arisk of dementia. Accumulating evidence suggests that MBI is highly prevalent in non-demented patients with PD, also being associated with an advanced disease stage, more severe motor deficits, as well as global and multiple-domain cognitive impairment. Neuroimaging studies have revealed that MBI in patients with PD may be related todistinct patterns of brain atrophy, altered neuronal connectivity, and distribution of dopamine transporter (DAT) depletion, shedding more light on its pathophysiological background. Genetic studies in PD patients have also shown that specific single-nucleotide polymorphisms (SNPs) may be associated with MBI, paving the way for future research in this field. In this review, we summarize and critically discuss the emerging evidence on the frequency, associated clinical and genetic factors, as well as neuroanatomical and neurophysiological correlates of MBI in PD, aiming to elucidate the underlying pathophysiology and its potential role as an early "marker" of cognitive decline, particularly in this population. In addition, we aim to identify research gaps, and propose novel relative areas of interest that could aid in our better understanding of the relationship of this newly defined diagnostic entity with PD.

Indexed as

Cognitive DysfunctionParkinson DiseaseAnxietyAnxiety DisordersHumansPolymorphism, Single Nucleotidecognitive declinedementiamild behavioral impairmentmild cognitive impairmentneuropsychiatric symptomsParkinson’s diseaseprodromal Parkinson’s disease

Identifiers

PMID38256375
PMCPMC10820007
OpenAlexW4390663295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.